

# Vahid Afshar-Kharghan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8574997/publications.pdf>

Version: 2024-02-01

46  
papers

3,246  
citations

304743

22  
h-index

276875

41  
g-index

46  
all docs

46  
docs citations

46  
times ranked

4855  
citing authors

#	ARTICLE	IF	CITATIONS
1	Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 104-114.	3.8	23
2	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 147-172.	5.9	6
3	Hyperadhesive von Willebrand Factor Promotes Extracellular Vesicle-Induced Angiogenesis. <i>JACC Basic To Translational Science</i> , 2022, 7, 247-261.	4.1	13
4	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. <i>Molecular Cancer Therapeutics</i> , 2022, , .	4.1	5
5	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2498.	3.7	12
6	Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. <i>Thrombosis Update</i> , 2021, 2, 100020.	0.9	15
7	The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. <i>Blood Advances</i> , 2021, 5, 1947-1951.	5.2	10
8	Losing control to bad relatives. <i>Blood</i> , 2021, 137, 3462-3463.	1.4	0
9	Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. <i>Science Advances</i> , 2021, 7, .	10.3	43
10	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	2.8	10
11	The interaction between the complement system and hemostatic factors. <i>Current Opinion in Hematology</i> , 2020, 27, 341-352.	2.5	20
12	OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. <i>Blood Advances</i> , 2020, 4, 3329-3342.	5.2	33
13	Kidney Injury in Murine Models of Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1920-1924.	2.0	6
14	APC ameliorates pulmonary complications in cGVHD. <i>Blood</i> , 2019, 134, 724-725.	1.4	1
15	The Platelet Lifeline to Cancer: Challenges and Opportunities. <i>Cancer Cell</i> , 2018, 33, 965-983.	16.8	390
16	Complement and clot. <i>Blood</i> , 2017, 129, 2214-2215.	1.4	21
17	Role of Platelet-Derived Tgf $\beta$ 1 in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5611-5621.	7.0	51
18	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	12.8	169

#	ARTICLE	IF	CITATIONS
19	Role of ADP receptors on platelets in the growth of ovarian cancer. <i>Blood</i> , 2017, 130, 1235-1242.	1.4	86
20	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. <i>Platelets</i> , 2017, 28, 99-102.	2.3	18
21	Erythropoietin and hepatocellular carcinoma: What is patients survival outcome?. <i>Journal of Clinical Oncology</i> , 2017, 35, e15660-e15660.	1.6	0
22	Atypical hemolytic uremic syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 217-225.	2.5	44
23	Platelets are not hyperreactive in patients with ovarian cancer. <i>Platelets</i> , 2016, 27, 716-718.	2.3	14
24	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. <i>BBA Clinical</i> , 2016, 6, 76-81.	4.1	26
25	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelialâ€“Mesenchymal Transition. <i>Journal of Immunology</i> , 2016, 196, 1412-1418.	0.8	66
26	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	8.2	101
27	von Willebrand factor is a cofactor in complement regulation. <i>Blood</i> , 2015, 125, 1034-1037.	1.4	73
28	Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14266-14271.	7.1	61
29	Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 602-610.	7.0	72
30	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2015, 5, 29.	2.8	3
31	Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1392-1398.	2.0	161
32	Platelet Function in Ovarian Cancer. <i>Blood</i> , 2015, 126, 4656-4656.	1.4	0
33	Autocrine Effects of Tumor-Derived Complement. <i>Cell Reports</i> , 2014, 6, 1085-1095.	6.4	164
34	Platelet Effects on Ovarian Cancer. <i>Seminars in Oncology</i> , 2014, 41, 378-384.	2.2	48
35	Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. <i>Blood</i> , 2014, 124, 184-187.	1.4	137
36	COMPLEMENTing the diagnosis of aHUS. <i>Blood</i> , 2014, 124, 1699-1700.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Heparin-induced thrombocytopenia among patients of a comprehensive cancer center. SAGE Open Medical Case Reports, 2014, 2, 2050313X1453394.	0.3	5
38	Complement activation in thrombotic microangiopathies. British Journal of Haematology, 2013, 160, 404-406.	2.5	17
39	Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood, 2013, 122, 1487-1493.	1.4	72
40	The Interaction between Factor H and Von Willebrand Factor. PLoS ONE, 2013, 8, e73715.	2.5	45
41	Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 610-618.	27.0	651
42	Platelets increase the proliferation of ovarian cancer cells. Blood, 2012, 120, 4869-4872.	1.4	190
43	Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism (VTE) Receiving Anticoagulation. Blood, 2012, 120, 3408-3408.	1.4	6
44	Reduced GVHD in C3-Deficient Mice Is Associated with a Decrease in Donor Th1/Th17 Polarization and Recipient Th1- Driven Dendritic Cell Activation. Blood, 2011, 118, 308-308.	1.4	0
45	Factor H Binds to Von Willebrand Factor (VWF) and Regulates Its Cleavage by ADAMTS-13. Blood, 2008, 112, 3935-3935.	1.4	0
46	Platelet activation leads to activation and propagation of the complement system. Journal of Experimental Medicine, 2005, 201, 871-879.	8.5	353